305 related articles for article (PubMed ID: 36040792)
1. Activation of targetable inflammatory immune signaling is seen in myelodysplastic syndromes with SF3B1 mutations.
Choudhary GS; Pellagatti A; Agianian B; Smith MA; Bhagat TD; Gordon-Mitchell S; Sahu S; Pandey S; Shah N; Aluri S; Aggarwal R; Aminov S; Schwartz L; Steeples V; Booher RN; Ramachandra M; Samson M; Carbajal M; Pradhan K; Bowman TV; Pillai MM; Will B; Wickrema A; Shastri A; Bradley RK; Martell RE; Steidl UG; Gavathiotis E; Boultwood J; Starczynowski DT; Verma A
Elife; 2022 Aug; 11():. PubMed ID: 36040792
[TBL] [Abstract][Full Text] [Related]
2. U2AF1 mutations induce oncogenic IRAK4 isoforms and activate innate immune pathways in myeloid malignancies.
Smith MA; Choudhary GS; Pellagatti A; Choi K; Bolanos LC; Bhagat TD; Gordon-Mitchell S; Von Ahrens D; Pradhan K; Steeples V; Kim S; Steidl U; Walter M; Fraser IDC; Kulkarni A; Salomonis N; Komurov K; Boultwood J; Verma A; Starczynowski DT
Nat Cell Biol; 2019 May; 21(5):640-650. PubMed ID: 31011167
[TBL] [Abstract][Full Text] [Related]
3. Splicing factor mutations in the myelodysplastic syndromes: Role of key aberrantly spliced genes in disease pathophysiology and treatment.
Pellagatti A; Boultwood J
Adv Biol Regul; 2023 Jan; 87():100920. PubMed ID: 36216757
[TBL] [Abstract][Full Text] [Related]
4. SF3B1 mutant myelodysplastic syndrome: Recent advances.
Pellagatti A; Boultwood J
Adv Biol Regul; 2021 Jan; 79():100776. PubMed ID: 33358369
[TBL] [Abstract][Full Text] [Related]
5. Disruption of SF3B1 results in deregulated expression and splicing of key genes and pathways in myelodysplastic syndrome hematopoietic stem and progenitor cells.
Dolatshad H; Pellagatti A; Fernandez-Mercado M; Yip BH; Malcovati L; Attwood M; Przychodzen B; Sahgal N; Kanapin AA; Lockstone H; Scifo L; Vandenberghe P; Papaemmanuil E; Smith CW; Campbell PJ; Ogawa S; Maciejewski JP; Cazzola M; Savage KI; Boultwood J
Leukemia; 2015 May; 29(5):1092-103. PubMed ID: 25428262
[TBL] [Abstract][Full Text] [Related]
6. Splicing factor mutant myelodysplastic syndromes: Recent advances.
Pellagatti A; Boultwood J
Adv Biol Regul; 2020 Jan; 75():100655. PubMed ID: 31558432
[TBL] [Abstract][Full Text] [Related]
7. Altered splicing and cytoplasmic levels of tRNA synthetases in SF3B1-mutant myelodysplastic syndromes as a therapeutic vulnerability.
Liberante FG; Lappin K; Barros EM; Vohhodina J; Grebien F; Savage KI; Mills KI
Sci Rep; 2019 Feb; 9(1):2678. PubMed ID: 30804405
[TBL] [Abstract][Full Text] [Related]
8. SF3B1 mutant-induced missplicing of MAP3K7 causes anemia in myelodysplastic syndromes.
Lieu YK; Liu Z; Ali AM; Wei X; Penson A; Zhang J; An X; Rabadan R; Raza A; Manley JL; Mukherjee S
Proc Natl Acad Sci U S A; 2022 Jan; 119(1):. PubMed ID: 34930825
[TBL] [Abstract][Full Text] [Related]
9. Splicing factor 3B subunit 1 (SF3B1) mutation in the context of therapy-related myelodysplastic syndromes.
Volpe VO; Al Ali N; Chan O; Padron E; Sallman DA; Kuykendall A; Sweet K; Lancet JE; Komrokji RS
Br J Haematol; 2022 Aug; 198(4):713-720. PubMed ID: 35751140
[TBL] [Abstract][Full Text] [Related]
10. Clinical significance of SF3B1 mutations in myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms.
Malcovati L; Papaemmanuil E; Bowen DT; Boultwood J; Della Porta MG; Pascutto C; Travaglino E; Groves MJ; Godfrey AL; Ambaglio I; Gallì A; Da Vià MC; Conte S; Tauro S; Keenan N; Hyslop A; Hinton J; Mudie LJ; Wainscoat JS; Futreal PA; Stratton MR; Campbell PJ; Hellström-Lindberg E; Cazzola M;
Blood; 2011 Dec; 118(24):6239-46. PubMed ID: 21998214
[TBL] [Abstract][Full Text] [Related]
11. Studying the connection between SF3B1 and four types of cancer by analyzing networks constructed based on published research.
Samy A; Ozdemir MK; Alhajj R
Sci Rep; 2023 Feb; 13(1):2704. PubMed ID: 36792691
[TBL] [Abstract][Full Text] [Related]
12. Splicing modulators impair DNA damage response and induce killing of cohesin-mutant MDS and AML.
Wheeler EC; Martin BJE; Doyle WC; Neaher S; Conway CA; Pitton CN; Gorelov RA; Donahue M; Jann JC; Abdel-Wahab O; Taylor J; Seiler M; Buonamici S; Pikman Y; Garcia JS; Belizaire R; Adelman K; Tothova Z
Sci Transl Med; 2024 Jan; 16(728):eade2774. PubMed ID: 38170787
[TBL] [Abstract][Full Text] [Related]
13. Erythroid Differentiation Enhances RNA Mis-Splicing in SF3B1-Mutant Myelodysplastic Syndromes with Ring Sideroblasts.
Moura PL; Mortera-Blanco T; Hofman IJ; Todisco G; Kretzschmar WW; Björklund AC; Creignou M; Hagemann-Jensen M; Ziegenhain C; Cabrerizo Granados D; Barbosa I; Walldin G; Jansson M; Ashley N; Mead AJ; Lundin V; Dimitriou M; Yoshizato T; Woll PS; Ogawa S; Sandberg R; Jacobsen SEW; Hellström-Lindberg E
Cancer Res; 2024 Jan; 84(2):211-225. PubMed ID: 37921711
[TBL] [Abstract][Full Text] [Related]
14. Paralog-specific signaling by IRAK1/4 maintains MyD88-independent functions in MDS/AML.
Bennett J; Ishikawa C; Agarwal P; Yeung J; Sampson A; Uible E; Vick E; Bolanos LC; Hueneman K; Wunderlich M; Kolt A; Choi K; Volk A; Greis KD; Rosenbaum J; Hoyt SB; Thomas CJ; Starczynowski DT
Blood; 2023 Sep; 142(11):989-1007. PubMed ID: 37172199
[TBL] [Abstract][Full Text] [Related]
15. Disease-Causing Mutations in SF3B1 Alter Splicing by Disrupting Interaction with SUGP1.
Zhang J; Ali AM; Lieu YK; Liu Z; Gao J; Rabadan R; Raza A; Mukherjee S; Manley JL
Mol Cell; 2019 Oct; 76(1):82-95.e7. PubMed ID: 31474574
[TBL] [Abstract][Full Text] [Related]
16. m
Cieśla M; Ngoc PCT; Muthukumar S; Todisco G; Madej M; Fritz H; Dimitriou M; Incarnato D; Hellström-Lindberg E; Bellodi C
Mol Cell; 2023 Apr; 83(7):1165-1179.e11. PubMed ID: 36944332
[TBL] [Abstract][Full Text] [Related]
17. Cryptic splicing events in the iron transporter ABCB7 and other key target genes in SF3B1-mutant myelodysplastic syndromes.
Dolatshad H; Pellagatti A; Liberante FG; Llorian M; Repapi E; Steeples V; Roy S; Scifo L; Armstrong RN; Shaw J; Yip BH; Killick S; Kušec R; Taylor S; Mills KI; Savage KI; Smith CW; Boultwood J
Leukemia; 2016 Dec; 30(12):2322-2331. PubMed ID: 27211273
[TBL] [Abstract][Full Text] [Related]
18. Splicing factor SF3B1K700E mutant dysregulates erythroid differentiation via aberrant alternative splicing of transcription factor TAL1.
Jin S; Su H; Tran NT; Song J; Lu SS; Li Y; Huang S; Abdel-Wahab O; Liu Y; Zhao X
PLoS One; 2017; 12(5):e0175523. PubMed ID: 28545085
[TBL] [Abstract][Full Text] [Related]
19. Impact of spliceosome mutations on RNA splicing in myelodysplasia: dysregulated genes/pathways and clinical associations.
Pellagatti A; Armstrong RN; Steeples V; Sharma E; Repapi E; Singh S; Sanchi A; Radujkovic A; Horn P; Dolatshad H; Roy S; Broxholme J; Lockstone H; Taylor S; Giagounidis A; Vyas P; Schuh A; Hamblin A; Papaemmanuil E; Killick S; Malcovati L; Hennrich ML; Gavin AC; Ho AD; Luft T; Hellström-Lindberg E; Cazzola M; Smith CWJ; Smith S; Boultwood J
Blood; 2018 Sep; 132(12):1225-1240. PubMed ID: 29930011
[No Abstract] [Full Text] [Related]
20. Epigenetic modifications of splicing factor genes in myelodysplastic syndromes and acute myeloid leukemia.
Wong JJ; Lau KA; Pinello N; Rasko JE
Cancer Sci; 2014 Nov; 105(11):1457-63. PubMed ID: 25220401
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
